Cyclopharm Limited

As of December 31, 2025, Cyclopharm Limited carries a market capitalization of 108.91M, placing it among publicly traded companies globally. Its enterprise value stands at 110.03M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Cyclopharm Limited's next confirmed earnings release is scheduled for February 24, 2027.

As of December 31, 2025, Cyclopharm Limited has 111.14M shares outstanding.

These figures are as of December 31, 2025. The price-to-sales ratio is 6.47, and the price-to-book ratio stands at 4.02.

These figures are as of December 31, 2025. The EV/Sales ratio of 6.59 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 110.03M versus a market cap of 108.91M, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2025, Cyclopharm Limited maintains a current ratio of 2.53, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 28.55, indicating elevated leverage, while an interest coverage ratio of -731.23 demonstrates limited ability to service its debt obligations.

Over the twelve months ended December 31, 2025, Cyclopharm Limited posted a negative return on equity (ROE) of -49.31, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -31.82, reflecting losses generated across the asset base. The company generates approximately 153,141.60 in revenue per employee across its workforce of 109.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.17 indicates how many times Cyclopharm Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended December 31, 2025, Cyclopharm Limited recorded an income tax benefit of -636,778.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -17.86M and -17.22M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Cyclopharm Limited's stock has declined approximately 48.57% over the past 52 weeks. The 50-day moving average sits at 0.48, while the 200-day moving average is 0.67.

Over the twelve months ended December 31, 2025, Cyclopharm Limited generated 16.69M in revenue and converted that into -17.22M in net income, yielding earnings per share of -0.16. EBITDA reached -35.39M, while operating income came in at -33.82M.

As of December 31, 2025, Cyclopharm Limited holds 6.63M in cash and equivalents against 7.74M in total debt, resulting in a net debt position of -6.63M. Total book value stands at 27.11M, with working capital of 17.20M providing operational flexibility.

These figures cover the twelve months ended December 31, 2025.

Over the twelve months ended December 31, 2025, Cyclopharm Limited posted a gross margin of 13.30, reflecting its pricing power and cost economics. The operating margin of -202.58 and net profit margin of -103.16 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2025. Total shareholder yield reaches 1.03, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Cyclopharm Limited shareholders.

Cyclopharm Limited's most recent stock split took place on June 8, 2017 with a 554:559 split ratio.

As of December 31, 2025, Cyclopharm Limited has an Altman Z-Score of -0.37, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.